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Background: Meta-analyses (MA) based on individual patient data (IPD) are regarded as the gold standard for
meta-analyses and are becoming increasingly common, having several advantages over meta-analyses of summary
statistics. These analyses are being undertaken in an increasing diversity of settings, often having a binary outcome.
In a previous systematic review of articles published between 1999–2001, the statistical approach was seldom
reported in sufficient detail, and the outcome was binary in 32% of the studies considered. Here, we explore
statistical methods used for IPD-MA of binary outcomes only, a decade later.
Methods: We selected 56 articles, published in 2011 that presented results from an individual patient data meta-analysis.
Of these, 26 considered a binary outcome. Here, we review 26 IPD-MA published during 2011 to consider: the
goal of the study and reason for conducting an IPD-MA, whether they obtained all the data they sought, the
approach used in their analysis, for instance, a two-stage or a one stage model, and the assumption of fixed or
random effects. We also investigated how heterogeneity across studies was described and how studies investigated
the effects of covariates.
Results: 19 of the 26 IPD-MA used a one-stage approach. 9 IPD-MA used a one-stage random treatment-effect logistic
regression model, allowing the treatment effect to vary across studies. Twelve IPD-MA presented some form of statistic
to measure heterogeneity across studies, though these were usually calculated using two-stage approach. Subgroup
analyses were undertaken in all IPD-MA that aimed to estimate a treatment effect or safety of a treatment,. Sixteen
meta-analyses obtained 90% or more of the patients sought.
Conclusion: Evidence from this systematic review shows that the use of binary outcomes in assessing the effects of
health care problems has increased, with random effects logistic regression the most common method of analysis.
Methods are still often not reported in enough detail. Results also show that heterogeneity of treatment effects is
discussed in most applications.
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A meta-analysis (MA) attempts to synthesize the results
from various distinct studies. The goal is to summarize
the evidence for a particular statistical measure of interest,
such as a risk difference or odds ratio. It is an especially
important tool in clinical practice and medical research,
where evidence-based information is preferred [1].
Individual patient data (IPD) MA are the gold stand-
ard of meta-analysis. In an IPD-MA line-by-line patient* Correspondence: andrea.benedetti@mcgill.ca
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unless otherwise stated.data are collected from the relevant studies, rather than
just the measure of effect as in a standard aggregate data
(AD) MA. This permits researchers to define exposures
and outcomes consistently across studies, and to analyze
them more similarly (e.g. adjusting for the same con-
founders), which may minimize heterogeneity [2,3].
For IPD-MA, two broad analytic strategies (one- and
two-step approaches) are possible; both preserve the clus-
tering of subjects within studies, comparability of study
arms, and both may be either fixed or random. A fixed ef-
fects analysis assumes that the estimated effect is the same
across all studies, while a random effects analysis assumesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ences in patient populations, study procedures, etc [1,4].
A two-step approach first analyzes each study separ-
ately and as identically as possible, and then uses stand-
ard meta-analytic techniques to pool the measure of
interest. The well-known random effects method of Der
Simonian and Laird is frequently used in the second step
of a two-step IPD-MA approach [1].
One step approaches use one statistical model while
accounting for the clustering among patients in the
same study, to estimate an overall effect. A one step
model also takes advantage of the ability to standardize
elements of the analysis across studies, but offers more
flexibility to explore the differences that may exist
between patients in the same study as well as across
studies [2,3,5]. In particular, a one-step approach allows
better control of confounding by patient- and study-
level covariates, improves power for detecting interactions
and subgroup analyses, as well as avoids and reduces the
potential for ecological bias that may occur if group level
information is included in the analysis [6,7].
In conventional AD-MA, it is difficult to estimate the ef-
fects of patient-level covariates on the treatment effect
[8,9]. In the context of an AD-MA, this is known as meta-
regression and may use study level covariates or aggregated
patient level information. Meta-regressions are prone to
ecological bias, and to confounding from variables not in-
cluded in the model [5,6,9] and may have limited power.
IPD-MA have higher power than meta-regression to detect
the effect of an interaction between covariates and treat-
ment, and are preferable when the interest is in estimating
interactions with patient-level covariates [9-11].
Importantly, IPD-MA are not prone to ecological bias
if inferences about individuals are not based on aggre-
gated data and model misspecification is evaded [6]. For
these reasons, and others, IPD-MA are considered the
gold standard of meta-analysis, despite the complexity
and cost of collecting the data, and are published with
increasing frequency [2].
Despite the many advantages, the wide range of methods
used for analysis of IPD-MA and the lack of a standardized
data analysis plan is a serious drawback [12,13]. A previous
review of methods used in practice for IPD-MA, reviewed
44 articles published during 1999–2001, of which 14
considered a binary outcome [13]. That review found
that the two-step approach was used about two-thirds
of the time [13].
The aim of this systematic review is to update that re-
port, nearly a decade later when random effects models
have been well integrated into other areas of health re-
search, are readily available in many software packages
and computing power is also up to the challenge. Our
objective was to investigate the statistical approach taken
to analyze IPD-MA with binary outcomes. In particular,we were interested in (i) whether two-stage or one-stage
approaches were more common; (ii) how heterogeneity
was investigated and reported; and (iii) if a one step ap-
proach was used, were intercepts permitted to vary
across primary studies considered as random.
Methods
Eligibility criteria for included studies were articles pub-
lished in 2011 that reported results of an individual pa-
tient data meta-analysis for a binary outcome and were
indexed in PUBMED or Medline. We believed that this
would provide a good overview of the methods currently
used for analysis of IPD-MA. We performed the search
in June 2012.
We searched in PUBMED and MEDLINE for articles
published between January 1, 2011 and December 30,
2011. The search terms used were “meta analysis” and
(“individual patient data” or “ipd” or “patient level” or
“individual participant” or “integrated analysis”). The ti-
tles and abstracts of these articles were reviewed to en-
sure that they reported results of an IPD-MA.
For the full text review, a standardized form was filled
independently by two reviewers (SR, DT). Discordant
entries were resolved by a third reviewer (AB). The data
we collected from each article included: the reason for
performing an IPD-MA, the goal of the IPD-MA, the
types of studies collected, the number of studies sought
and retrieved; the number of patients sought and re-
trieved; the type of outcome (e.g., binary, time-to-event
or continuous); the method of analysis for the primary
outcome and whether the analytic approach was one-
stage or two-stage; whether intercept and/or the treat-
ment effect were allowed to vary across studies (fixed or
random effects); how heterogeneity was quantified, ad-
dressed and reported; the method of analysis of covari-
ates: whether by one- or two-stage methods; methods
for study- or patient-level covariates; and, whether sub-
group analyses were performed (See Additional file 1:
Table S1). For this review, we have considered only those
articles which used a binary outcome.
We present descriptive analyses only.
Results
A total of 111 articles were returned from our search
strategy. The titles and abstracts of these articles were
reviewed to ensure that they reported results of an indi-
vidual patient data meta-analysis. On this basis, 56 were
selected for full text review. Articles excluded did not re-
port results from an individual patient data meta-analysis
(See Figure 1).
Twenty-seven articles presented time-to-event outcome
data, 2 presented continuous outcome data and only one
article had a count outcome. We focus on the 26 articles
that presented results using a binary outcome.
Figure 1 Flowchart of the inclusion of Individual patients data meta-analyses.
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estimate diagnostic accuracy (5, 19%) [14-18]; to esti-
mate a treatment or exposure effect (14, 53%) [19-32], to
identify predictors of an outcome (4, 15%) [23,33-35], to
investigate safety of a treatment (3, 12%) [32,36,37], or
other reason or goal not specified (2, 8%) [38,39]. (Note
that percentages may not total to 100, because more
than one goal was possible) (See Table 1).
Over half of IPD-MA (15/26) included only randomized
control trials while the other IPD-MA included only ob-
servational studies. IPD-MA that included observational
studies had a different profile in terms of goal with a
greater proportion of studies that aimed to estimated diag-
nostic accuracy, and fewer IPD-MA that aimed to esti-
mate the effect or safety of a treatment (See Table 1).Table 1 Goal of study, overall and stratified according to whe
trials, or included both randomized controlled trials and obse
Reason Included only randomize
controlled trials (n = 15)
To estimate a treatment effect 10 (67%)
To investigate safety of a treatment 2 (13%)
To estimate diagnostic accuracy 1 (7%)
To identify predictors 1 (7%)
Other/Unclear 2 (13%)
1Numbers may not total to 100% because some IPD-MA had more than one goal.Why IPD?
When carrying out an IPD-MA, there are several advan-
tages to be gained from this approach over aggregated data
meta-analyses. The main reasons for adopting the IPD
method reported for these 26 articles are summarized in
Table 2. Half the studies included in our review cited sub-
group analyses as the reason for conducting the IPD-MA.
Numbers of studies and patients
Figures 2 and 3 present the number of studies and num-
ber of patients included in the IPD-MA, respectively.
More than 90% of the meta-analyses presented results for
both the number of studies and patients obtained and
sought. The median number of studies was 12, with inter-





studies (n = 11) N (%)
Overall N (%)
3 (27%) 13 (50%)
1 (9%) 3 (12%)
4 (36%) 5 (19%)
3 (27%) 4 (15%)
1 (9%) 3 (12%)
Table 2 Reasons provided to support conducting an IPD1
Reason N (%)
To perform subgroup analyses 13 (50%)
To improve consistency across studies
(in terms of inclusion criteria, outcome definition, etc.)
4 (15%)
To consider other outcomes 4 (15%)
To adjust for confounding variables 1 (4%)
To estimate diagnostic accuracy 5 (19%)
To identify predictors of an outcome 2 (8%)
Unclear 6 (23%)
1Percentages do not total to 100 because some studies reported more than
one reason for conducting an IPD-MA.
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with fewer than ten studies, to five with more than twenty
studies.
More variation was observed in the number of patients
obtained, with median and inter-quartile range of 2964
and 679–4291 respectively (See Figure 3). Three meta-
analyses had more than 10,000 patients and nine had
fewer than 1000 patients.
Figure 4 shows the percentage of patients sought for
which the full data were obtained. Sixteen (62%) meta-
analyses obtained 90% or more of the total number of
patients. Of these, eleven (69%) publications obtained in-
formation on all of the patients sought. The median of the
16 IPD-MA was 3430 with IQR of 908–6500 patients.
Statistical methods
Although many studies reported results for more than
one outcome, here, we focus on the methods used to
analyze the binary outcome. A majority of analyses con-
centrated on mortality or a dichotomized scale for the
binary outcome. Most analyses used a one-stage method
to pool the overall effect (69%) in the 26 IPD-MA for
binary outcomes (Table 3). In those papers that used the
one stage approach, usually all patient data from these
studies were combined in a generalized linear mixedFigure 2 Number of studies from which IPD were obtained.model (GLMM), accounting for the clustering among
patients from the same study by including random study
and or treatment effects. In general, few details were
provided, and information often had to be inferred based
on the results presented.
Among the 19 one-stage analyses, logistic regression
was the most frequent technique employed. Ten of these
IPD-MA used a random effects analysis. However, in 5
of these it was not clear whether intercepts, treatment
effects or both were allowed to vary across studies. In
the remaining 5 IPD-MA, 2 allowed both intercepts and
treatment effects to vary, 1 allowed only the treatment
effect to vary, and 2 allowed only the intercepts to vary. In
general, little justification was offered for these choices.
None specified the estimation method (e.g. penalized
quasi-likelihood (PQL) [40] or adaptive Gaussian Hermite
quadrature [41], etc.) used.
A fixed effects one-stage approach was used in 9 IPD-
MA. Of these, 5 IPD-MA seemed to ignore clustering of
subjects by study completely, and pooled all subjects
together.
Two-stage methods were used in 6 of 26 studies
reviewed. Of these, three studies used random effects for
the treatment. One study initially used a Der Simonian
Laird approach, but due to very low estimated hetero-
geneity, used a fixed treatment effect. The Cochrane-
Mantel-Haenszel two-stage approach was used in one
study, where no indication of heterogeneity across stud-
ies was found.
Heterogeneity
Most IPD-MA (n = 20) explicitly quantified heterogen-
eity across included studies. (See Table 4) The most fre-
quently used measures were the Q statistic and I2 [42],
which were used in 12 studies. In five studies, other
measures of heterogeneity were reported, such as the es-
timated variance from the random effects model or the
inclusion of an interaction term in a model. It was un-
clear if any measure of heterogeneity was used in 6
Figure 3 Number of patients from which IPD were obtained.
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heterogeneity was presented. Two studies used multiple
estimates to quantify heterogeneity; these estimates were
the I2 and Q statistics and the Breslow-Day and Q statis-
tic [30]. Seven studies used a one step approach but re-
ported measures of heterogeneity based on a two-step
model, while the other studies used various techniques
to assess and report heterogeneity.
Covariates
Covariates were used in three ways: (i) to assess subgroup
effects; (ii) to adjust a treatment effect for possible con-
founders; and (iii) to identify predictors of an outcome.
Among the 16 studies where the goal of the IPD-MA
was to estimate a treatment effect or the safety of a treat-
ment, all considered subgroup analyses. Among studies
that reported the number of subgroups considered, the
median number of subgroups investigated was 2.5, with a
range from 1–15. In all but one case, subgroups were
formed by using categorical variables or categorizing a
continuous variable. In one study, an interaction between
the treatment and a continuous or ordinal risk score was
evaluated. The subgroups investigated were based on
patient-level characteristics in 13 IPD-MA, and on both
patient- and study-level characteristics in 3 IPD-MA.Figure 4 Percentage of patients sought that were obtained.Among the studies that used a one-stage approach, 9/10
included interaction terms in the model, and presented
stratum specific estimates as well as a p-value for the
interaction. Among studies that used a two stage ap-
proach, 5/6 presented the stratum specific effect estimates,
and 5/6 presented a p-value for the interaction. In two
cases this p-value was calculated as described in [43].
Among the 3 IPD-MA that included observational
studies and aimed to estimate a treatment effect or
safety, all three adjusted for potential patient-level con-
founders. One of these studies used a two-step approach
first adjusting for confounders in each study separately
then pooling the adjusted effect estimates. Among the
IPD-MA that only included randomized trials, and
aimed to estimate a treatment effect or safety (n = 13),
only 2 adjusted for patient level confounders. They did
so by including them in a one stage model.
Finally, of the four IPD-MA that aimed to identify pre-
dictors of an outcome, three included observational
studies.
Missing data
While there are a number of approaches that could be
taken to deal with missing data, 16/26 IPD-MA did not
report how missing data were handled. Three studies used
Table 3 Statistical analysis method categorized by overall
strategy among 26 IPD meta-analyses of binary
outcomes
Analytic approach1 n/N (%)
One stage approach (n = 19)
Ignored clustering by study Logistic regression 5/19 (26%)
Fixed effects Logistic regression 4/19 (21%)
Random effects Logistic regression 10/19 (52%)
Fixed study effect with
random treatment effect2
1/10 (10%)
Random study effect with
fixed treatment effect2
2/10 (20%)




Two stage approach (n = 6)
Fixed effects Unspecified 2/6 (33%)
Cochrane-Mantel-Haenszel 1/6 (17%)
Random effects Der Simonian Laird 2/6 (33%)
Unspecified 1/6 (17%)
1It was unclear from one article [38] which approach was used.
2Among studies that used random effects logistic regression, where the
intercepts and/or treatment effects allowed to vary across studies.
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ation. The remaining studies used a variety of other ap-
proaches to dealing with missing data including excluding
subjects with missing data, or excluding variables with too
much missing data, or it was unclear what approach was
taken.
Discussion
In this paper, we reviewed a sample of published individ-
ual patient data meta-analyses where the primary out-
come was dichotomous, focusing on the statistical
approach taken and results reported. To identify relevant
articles in our review, we used a thorough search strat-
egy and assessed 26 IPD MA articles published in the
year 2011 that presented results for a binary outcome. It
is possible that some relevant papers that reported the
results of IPD MA with binary outcomes and wereTable 4 Statistic used to measure heterogeneity among
studies in the 26 IPD meta-analyses stratified by analytic
approaches
Statistics





(N = 6) (N = 6) (N = 2) (N = 6) (N = 6)
n (%) n (%) n (%) n (%) n (%)
One-step 3 (50) 4 (67) 0 (0) 6 (100) 6 (100)
Two-step 2 (33) 2 (33) 2 (100) 0 (0) 0 (0)published in 2011 have been missed or excluded uninten-
tionally, but these would be unlikely to differ substantially
methodologically than those included. Two reviewers ex-
tracted all information independently and a third reviewer
resolved conflicts. It might also be possible due to the lack
of sufficient details to distinguish the methods used, that
methods were incorrectly classified since the precise
method used was sometimes inferred.
This review also highlighted the strengths and weak-
nesses of individual patient data meta-analyses (IPD-
MA) where the outcome was binary. IPD-MA are clearly
the gold standard of meta-analytic methods and publica-
tions featuring results from IPD-MA are growing stead-
ily in recent years. However, there are considerable
variations in the methodology employed, for instance,
the use of fixed or random effects for the estimated ef-
fect measures, measures of heterogeneity and strategies
used to estimate treatment effects. In many studies, the
statistical aspects were not clearly reported, with insuffi-
cient details provided to distinguish the methods used.
Most times, little justification was given for the ap-
proaches taken in the studies, perhaps due to the lack of
specific guidelines available for the IPD meta-analysis of
binary outcomes. While guidelines exist for the reporting
of systematic reviews and meta-analyses, these guidelines
are not specific to IPD-MA. For example, the PRISMA
guideline #14 suggests that the methods of handling
data and combining results, including measures of het-
erogeneity be described [44]. Extending those guide-
lines to encompass issues specific to IPD MA, such as
stating if a one- or two-stage approach was used, would
likely improve the reporting of IPD meta-analyses of
binary outcomes.
In a previous systematic review of articles published in
1999–2001 [13], 14 (32%) of the IPD -MA dealt with a
binary outcome. While the proportion was similar, we
found nearly twice the number of IPD-MA of a binary
outcome in just one year in 2011.
This review of 26 IPD meta-analyses of binary out-
come encouragingly shows that practitioners often ob-
tain a large proportion of the IPD required. IPD from
90% or more of the total number of studies were ob-
tained in 62% of IPD studies, an important improvement
to the 41% found in the previous review [13].
We found that more than half (73%) of studies did not
use a two-step approach (i.e. analyzing each study separ-
ately and as identically as possible and pooling via stand-
ard meta analytic methods) but instead used the more
flexible one-stage method. This finding was contrary to
the previous review [13], in which most analyses were
performed using a two-stage approach (82%) with little
consideration of the one-step approach. This finding
likely reflects the greater comfort with random-effects
models for binary outcomes in health research, as these
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readily available in most mainstream statistical packages.
Heterogeneity was considered in some manner by 81%
of included reviews, whether by known quantitative
measures or other assessments. The most frequently used
measure of heterogeneity was the I2 statistic. Alternative
measures included the Q Statistic (Chi-square statistic),
and Breslow-Day test. In a few instances, heterogeneity
was estimated and reported from a two-stage approach;
even when a one-stage approach was used for the main
analysis.
Investigating subgroup effects was one of the primary
reasons for conducting an IPD-MA, and among IPD-MA
that aimed to estimate a treatment effect or treatment
safety all investigated subgroup effects. On the other hand,
IPD-MA were unlikely to adjust for potential confounders
unless observational studies were included.
Within the realm of IPD-MA with binary outcomes,
our review shows that a variety of methods were used to
estimate a pooled treatment effect. Many of the articles
reviewed contained insufficient details on the approach
used and the rationale for that approach. We next pro-
vide some recommendations and emphasize the use of
the PRISMA statement to help authors ensure transpar-
ent and complete reporting of systematic reviews and
meta-analyses [3,44,45]. First, if individual raw data is
available for all studies and irrespective of the final ap-
proach, most statisticians and methodologists prefer the
one-stage rather than a two-stage approach [2]. In some
cases, the one- and two-stage approaches will give simi-
lar results [46]. However, it is currently unknown under
what conditions this may be expected. Moreover, one
stage methods may be preferred for evaluating treatment-
covariate interactions of continuous covariates, incorpor-
ating nonlinear relationships, when studies are small, and
there is heterogeneity across studies, and particularly for
pooling of non randomized trials that may need to be ad-
justed for several confounders [46].
Moreover, methods have been developed to incorpor-
ate both individual patient data with summary level data
when necessary, so that having partial IPD should not be
an impediment to using a one-stage approach [5,11].
However, when random effects logistic regression is
used, several details should be reported including: whether
study and/or treatment were considered as random, and
the statistical method used to estimate the GLMM (e.g.
PQL or adaptive Gaussian Hermite quadrature). On the
other hand, if a two-stage approach is used, we suggest
that the meta-analytic technique used to pool results
should be stated explicitly. Moreover, simply pooling sub-
jects from various studies together is not appropriate.
Assessment and exploration of heterogeneity should
always be performed in any MA, or IPD-MA. Nonethe-
less, how best to quantify heterogeneity remains unclear.While some advocate using the estimated variance of
the random treatment effect, difficulties with its inter-
pretation may imply that I2 as estimated from a two-
stage approach is the optimal choice for quantifying het-
erogeneity. Of course, whether heterogeneity estimated
from a two-stage approach is relevant to a one-stage
model is an open question.
There are some limitations to the work presented here.
First, we have focused on binary outcomes, while sur-
vival outcomes were reported in about half of the studies
retrieved (See Figure 1). Second, we limited our study
retrieval to articles published in 2011. This choice was
made because this gave us a sufficient sample of studies
to work with that were recently completed. Moreover,
we believe that there are unlikely to be major differences
in the methods used, or in how they were reported be-
tween e.g. 2010 and 2011. Finally, we have focused only
on the statistical approach used in these studies; whereas
some may be interested more generally in how well IPD-
MA are reported.
Conclusion
As found previously, we have demonstrated that a diver-
sity of methods are employed when dealing with IPD
meta-analyses for binary outcomes. Evidence from this
systematic review shows that the use IPD-MA of binary
outcomes has increased, with random effects logistic re-
gression the most common method of analysis. The stat-
istical approach taken, along with justification for that
approach, is still often not reported in sufficient detail.
Standardized guidelines both for the best approach to
use, as well as what details to report may be needed in
this area.
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